Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint in Degenerative Disc Disease
NCT03246399Phase 1Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lorecivivint in degenerative disc disease (DDD) (3 arms), sponsored by Biosplice Therapeutics. Primary endpoints: Treatment Emergent Adverse Events at Day 180, Change from baseline in electrocardiogram parameters at Day 180 and 8 more. Started Jul 2017; status: terminated.
02
Drugs
lorecivivint
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03246399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246399.